Klonoff DC, et al. - In participants with type 1 diabetes (T1D), researchers assessed the effectiveness and safety of fast-acting insulin aspart (faster aspart) vs insulin aspart (IAsp) used in continuous subcutaneous insulin infusion (CSII). Between July 2016 and July 2017, 472 participants were randomized to CSII treatment with either faster aspart (n = 236) or IAsp (n = 236). The overall rate of severe or blood glucose- confirmed hypoglycemia was not statistically significantly different. The results obtained from this double-blind, treat-to-target, randomized, 16-week trial indicate that faster aspart offers a safe and efficacious option for CSII treatment in T1D patients, with improved postprandial glucose control reflected in meal-test and continuous glucose monitoring results.